DHFR and cancer: Previous findings have demonstrated that the MTX analog bearing a 2,4-diaminoquinazoline instead of a 2,4-diaminopteridine moiety (such as 3, Figure 1) inhibits DHFR with the same binding affinity and presents slightly increased cytotoxic activity against cancer cells [15,16].